Chengzhi Zhou

24PUBLICATIONS
67CO-AUTHORS
Molecular targetsMedical infection agents (incl. prions)Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Aug 12, 2026
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

|May 16, 2026
Disrupting SOX2 self-association and condensate formation to overcome chemotherapeutic drug resistance in lung squamous cell carcinoma.

|Sep 12, 2025
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis.

Haiyi Deng, Yi Yang, Yilin Yang

|Jan 06, 2025
Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3/GSDME-mediated pyroptosis.

Fei Wang, Haiyi Deng, Maolin Zhou

|Aug 08, 2024
A Nomogram for Predicting Cancer-Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk Model.

Jiaxin Li, Bolin Pan, Qiying Huang

|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gen Lin, Zhijie Wang, Qian Chu

Pageof 4

Frequent Collaborators

8 joint publications

Yong Song

8 joint publications

Chunwei Xu

8 joint publications

Wenxian Wang

7 joint publications

Yongchang Zhang